In terms of molecular subtypes, BC patients were classified as Luminal‐A (44.5%), Luminal‐B (22.4%), Triple‐negative breast cancer (TNBC) (22.1%), and HER2 enriched (11%) (Table 2). Here, ERBB2 is linked to breast cancer.